期刊文献+

缩泉丸对肾阳虚多尿大鼠肾脏AVPR-V2表达的影响 被引量:4

Impacts of the formula of suoquanwan (SQW) on expression of AVPR-V2 in the kidney of rat polyuria model of yang-deficiency
暂未订购
导出
摘要 目的观察缩泉丸对肾阳虚多尿模型大鼠肾脏加压素二型受体(AVPR-V2)表达的影响。方法用腺嘌呤250mg/kg灌服大鼠4周,造成肾阳虚多尿模型,分别给予缩泉丸、肾气丸和去氨加压素治疗4周,用免疫组化法检测缩泉丸对肾阳虚多尿模型大鼠肾脏AVPR-V2表达的影响。结果模型组肾小球、集合管、肾小管和肾小囊的内壁细胞上AVPR-V2的表达明显较正常组减弱,表现为棕黄色颗粒明显减少,颜色明显变浅,dDAVP组和缩泉丸高剂量组肾脏AVPR-V2表达比模型组明显升高。结论缩泉丸能够改善肾阳虚多尿模型大鼠肾脏AVPR-V2的表达。 Objective To observe the impacts of the formula of Suoquanwan(SQW) on expression of AVPR-V2 protein in the Kidney of rat polyuria model of Yang-deficiency. Method The model rats were induced by adenine (250mg/kg) for 4 weeks,then treated respectively with SQW,Shenqiwan and dDAVP. Expression of AVPR-V2 in kidney of Yang-deficiency model by immunohistochemistry method was investigated. Results In model rats,expression of AVPR-V2 in the plasma of the wall cells of glomerulus,collecting duct,renal tubule and Bowman capsule were deceased, dDAVP and SQW high dose can increased the expression of AVPR-V2 protein in the Kidney. Conclusion SQW can increase expression of AVPR-V2 protein in the Kidney of the rat polyuria model of Yang-deficiency.
机构地区 广州中医药大学
出处 《中国老年保健医学》 2009年第3期12-14,共3页 Chinese Journal of Geriatric Care
基金 国家教育部博士点基金资助(20060572015)
关键词 缩泉丸 肾阳虚多尿 AVPR—V2 Suoquanwan,polyuria model of Yang-deficiency,AVPR-V2
  • 相关文献

参考文献2

二级参考文献35

  • 1Hidenori Ogawa , Hiroshi Yamamura, Kazumi Kondo ,et al.Orally active ,nonpetide vasopressin V2 receptor antagonists: a novel series of 1 - [4- (Benzoylamino) benzoyl]- 2,3,4,5-tetrahydro-1H-benzazepines and related compouneds[J].J Med Chem, 1996,39(18) : 3547-3555.
  • 2J Prous,N Mealy,J Casaner.OPC-31260[J]. Drugs Fut,1993,17 (9) : 802-804.
  • 3Kazumi Londo, Hideno Riogawa, Hiroshi Yamashita, et al.7-Chloro-5-hydroxy-1-[-2-methyl-4-( 2- methybenzoyl-amino)benzoly]-, 2, 3, 4,5- tetrahydro- 1 H- 1- benzazapine(OPC- 41260) : a potent, orally active nonpeptide arginine vasopressin V2 receptor antagonist[J]. Bioorg Meg Chem,1999. (7). 1743-1754.
  • 4Conivaptan hydrochloride[J].Drugs Fur, 2002,27 (1) : 72.
  • 5Akira Matsuhisa, Nobuaki Taniguchi, Hiroyuki Koshio, et al. Nonpeptide arginine vasopressin antagonists for both Vla and V2 receptors: synthesis and pharmacological properties of 4′-(1, 4, 5, 6- tetrahydroimidazo [4, 5-d] [1] ben-zoazepinc,-6-carbonyl) benanilide derivatives and 4′- ( 5,6-dihydro-4H-thiazolo[5,4-d][1] benzoazepine-6-carbonyl)benzanide derivatives [J ]. Chem Pharm Bull, 2000,4 8 ( 1 ) :21-31 .
  • 6Yasuhiro Ohtake ,Akira Naito ,Hisashi Hasegawa ,et al. Nov-el vasopressin V2 receptor-selective antagonists, pyrrolo[2,1 -a] quinoxaline and pyrrolo [- 2,1 - c ] [ 1,4 ] benzodiazepine derivatives[J]. Bioorg Med Chem, 1999, (7) : 1247-1254.
  • 7Aklra Naito, Yasuhiro Ohtake ,Hisashl Hasegawa,et al.Pharmacological profile of VP-343,a novel selective vaso-pressin V2 receptor antagonist,in rat[J]. Boil Pharm Bull,2000,23(2) : 182-189.
  • 8Serradeil-Le Gal C. An overview of SR121463, a selective non-peptide vasopressin V (2) receptor antagonist[J]. Car-diovasc Drug Rev, 2001,19(3) :201-214.
  • 9Hariharan Venkatsan, Mattew C Davis, Yesim Altas. Total synthesis of SR 121463A,a hightly potent and selective va-sopressin V2 receptor antagoltist[J]. J Org Chem, 2001, 66(11):3653-3660.
  • 10J D Albright,M F Reich,E G D Santos,et al. 5-Fluoro-2-methyl-N-[-4-5H-pyrrolo[- 2 ,-c-)- [- 1, 4 -) benzodiazepine- I 0(11H)-ylcarbonyl]- 3- chtoeiphenyl -) benzamide ( VPA-985) :an orally active arginine vasopressin antagonist with selectivity for V2 receptors [J]. J Mel Chem, 1998, 41:2442-2444.

共引文献12

同被引文献56

引证文献4

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部